<DOC>
	<DOCNO>NCT02394782</DOCNO>
	<brief_summary>This 24-month , observational , prospective , multinational , multicenter study determine relationship relapse ( percentage relapse free subject ) adherence subject diagnose RRMS treat Rebif ( interferon beta-1a ) use RebiSmart®2.0 MSdialog™ .</brief_summary>
	<brief_title>Observational Study Rebismart®2.0 + MSdialog™ Subjects With Remitting Multiple Sclerosis ( ADHERQOL )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Diagnosed RRMS accord McDonald criterion 2010 Relapse free within 30 day Baseline data collection Treatment Rebif 6 month prior inform consent Already use RebiSmart®2.0 + MSdialog™ patient report outcome ( PRO ) assessment ( least prior informed consent ) Females childbearing potential must willing use appropriate contraception duration study EDSS score le ( &lt; ) 6 Written inform consent obtain prior protocolrequired data collection Participation study within 30 day Baseline Female pregnant breast feeding Significant psychiatric symptom , opinion Investigator , would impact subject ability comply treatment ( per standard clinical practice ) Any contraindication Interferon ( IFN ) beta1a therapy per Summary Product Characteristics ( SPC ) Administration Multiple Sclerosis ( MS ) therapy , Rebif , within 6 month prior inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Multiple sclerosis , relapsing-remitting</keyword>
	<keyword>Rebif</keyword>
	<keyword>Interferon beta-1a</keyword>
	<keyword>RebiSmart®2.0</keyword>
	<keyword>MSdialog™</keyword>
</DOC>